- Home
- AMAL vs PHVS Comparison
AMAL vs PHVS Comparison
Compare AMAL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- PHVS
- Stock Information
- Founded
- AMAL 1923
- PHVS 2015
- Country
- AMAL United States
- PHVS Switzerland
- Employees
- AMAL N/A
- PHVS N/A
- Industry
- AMAL Commercial Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- PHVS Health Care
- Exchange
- AMAL Nasdaq
- PHVS Nasdaq
- Market Cap
- AMAL 937.6M
- PHVS 980.3M
- IPO Year
- AMAL 2018
- PHVS 2021
- Fundamental
- Price
- AMAL $32.94
- PHVS $22.32
- Analyst Decision
- AMAL Buy
- PHVS Buy
- Analyst Count
- AMAL 2
- PHVS 6
- Target Price
- AMAL $38.50
- PHVS $37.17
- AVG Volume (30 Days)
- AMAL 197.0K
- PHVS 30.0K
- Earning Date
- AMAL 07-24-2025
- PHVS 08-13-2025
- Dividend Yield
- AMAL 1.68%
- PHVS N/A
- EPS Growth
- AMAL 9.81
- PHVS N/A
- EPS
- AMAL 3.36
- PHVS N/A
- Revenue
- AMAL $303,970,000.00
- PHVS N/A
- Revenue This Year
- AMAL $11.72
- PHVS N/A
- Revenue Next Year
- AMAL $12.48
- PHVS N/A
- P/E Ratio
- AMAL $9.92
- PHVS N/A
- Revenue Growth
- AMAL 7.13
- PHVS N/A
- 52 Week Low
- AMAL $25.03
- PHVS $11.51
- 52 Week High
- AMAL $38.19
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- AMAL 63.07
- PHVS 73.31
- Support Level
- AMAL $32.82
- PHVS $17.63
- Resistance Level
- AMAL $33.58
- PHVS $19.00
- Average True Range (ATR)
- AMAL 0.69
- PHVS 1.20
- MACD
- AMAL 0.15
- PHVS 0.35
- Stochastic Oscillator
- AMAL 81.70
- PHVS 92.15
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.